Skip to content

Contents of Circulating Extracellular Vesicles: Biomarkers in Colorectal Cancer Patients

Contents of Circulating Extracellular Vesicles: Biomarkers in Colorectal Cancer Patients

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04523389
Acronym
ExoColon
Enrollment
172
Registered
2020-08-21
Start date
2020-07-01
Completion date
2026-03-18
Last updated
2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

Most cancer-related deaths are caused by distant metastases, which are tumour cells that have escaped from a primary tumour and passed into the bloodstream to colonize a new organ. In this context, communication between tumour and stromal cells is essential. Indeed, tumor cells interact with cells in the tumor microenvironment and are able to modify them to their advantage. Both extracellular vesicles (EVs) and exosomes are heterogeneous populations of small vesicles present in the tumor microenvironment and in body fluids that have recently emerged as powerful mediators involved in this communication and their transport in fluids. Tumor cells release large quantities of exosomes containing tumor markers, which can then spread to distant locations. The exosomes are of endosomal origin. They are composed of proteins, lipids, RNA and DNA, and they circulate in the bloodstream. They can be internalized by specific distant cells and thus deliver a functional message. It has recently been shown that tumor exosomes containing pro-metastatic factors form pre-metastatic niches, before the tumor cells actually arrive, while determining the metastatic organotropism of tumors. These properties are now opening up new avenues of research in tumor biomarkers. In recent years, several studies have highlighted different markers contained specifically in exosomes derived from cancer cells. Consequently, exosomes are considered as potential reservoirs of tumor biomarkers that could be clinically useful for the non-invasive diagnosis of cancer, with the advantage of being performed by liquid biopsy. The study of microRNA (miRNA) is of particular interest. Indeed, miRNAs are small non-coding RNAs (between 21 and 25 nucleotides) involved in the regulation of gene expression and which are frequently deregulated in cancer. Several studies underline that the variation of free miRNAs in the blood is correlated with the progression of the disease, particularly in colon cancer. However, the stability of free miRNAs is controversial. Therefore, exosomes represent a very advantageous means of transporting miRNAs in the blood, as they are able to protect miRNAs from degradation by RNAase. The hypothesis of the project is that circulating exosomes derived from tumours contain markers including specific miRNAs that could be used as biomarkers of early prognosis (survival and progression), easily measured in blood samples from patients with colon cancer. But other molecules contained in exosomes could also be of interest.

Interventions

BIOLOGICALanalysis (protein, lipid, RNA ...) of circulating exosomes, size and number

use of blood samples stored at the Ferdinand Cabanne Biological Resource Centre

OTHERGathering additional information about the patient's cancer

Gathering additional information about the patient's cancer, its treatment and its sequelae from the patient's medical record.

DIAGNOSTIC_TESTDiagnostic test

Diagnostic test

Sponsors

Centre Hospitalier Universitaire Dijon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Person included in the AGARIC study * Person who provided consent or non-opposition to inclusion in the study * Available blood sample in the AGARIC biobank at the Biological Resource Centre (Dijon)

Exclusion criteria

NA

Design outcomes

Primary

MeasureTime frameDescription
Prognostic role of exosomes and their contents on the survival of colorectal cancer patientsthroughout the study a average of 1 yearmain criterion of judgment: occurrence of death until 30/06/2020
Association between the number and size of exosomes and their content on cancer stage and progressionthroughout the study a average of 1 year* cancer stage to diagnosis * progression of the disease assessed according to the RECIST criteria and defined as (i) local-regional relapse, (ii) distant relapse, (iii) metastasis, (iv) development of another cancer until 30/06/2020.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026